Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
It is very uncertain whether summary of findings table ‐ Topical small molecule inhibitors… changes incidence of serious adverse events compared with placebo (very low certainty).
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
Vedolizumab showed no clear difference in serious adverse events (52–60 weeks) compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Antibiotics changes adverse events considered non‐serious compared with placebo or no intervention (very low certainty).
The review found no eligible studies for this question.
Bevacizumab + IFN probably leads to higher serious adverse events (Grade 3 or 4) compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (moderate certainty).
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).